Cargando…
Methylomic biomarkers of lithium response in bipolar disorder: a clinical utility study
BACKGROUND: Response to lithium (Li) is highly variable in bipolar disorders (BD). Despite decades of research, no clinical predictor(s) of response to Li prophylaxis have been consistently identified. Recently, we developed epigenetic Methylation Specific High-Resolution Melting (MS-HRM) assays abl...
Autores principales: | Marie-Claire, C., Courtin, C., Bellivier, F., Gard, S., Leboyer, M., Scott, J., Etain, B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148930/ https://www.ncbi.nlm.nih.gov/pubmed/37119343 http://dx.doi.org/10.1186/s40345-023-00296-6 |
Ejemplares similares
-
Methylomic Biomarkers of Lithium Response in Bipolar Disorder: A Proof of Transferability Study
por: Marie-Claire, Cynthia, et al.
Publicado: (2022) -
Circadian biomarkers in patients with bipolar disorder: promising putative predictors of lithium response
por: Geoffroy, Pierre Alexis, et al.
Publicado: (2014) -
Transcriptomics and miRNomics data integration in lymphoblastoid cells highlights the key role of immune-related functions in lithium treatment response in Bipolar disorder
por: Cattane, Nadia, et al.
Publicado: (2022) -
Can an Integrated Science Approach to Precision Medicine Research Improve Lithium Treatment in Bipolar Disorders?
por: Scott, Jan, et al.
Publicado: (2018) -
A DNA methylation signature discriminates between excellent and non-response to lithium in patients with bipolar disorder type 1
por: Marie-Claire, C., et al.
Publicado: (2020)